Skip to Main Content

Author Details

Dorian LaTocha
Knight Cancer Institute, Oregon Health & Science University
2000
19
16
PMIDPaper TitleJournal TitlePublished Year
35710794Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.Nat Commun2022
32898857Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.Blood2021
34233449Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia.Haematologica2021
31784538Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.Nat Commun2019
25759025Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.Cancer Cell2015
262874946-Formylindolo(3,2-b)Carbazole (FICZ) Modulates the Signalsome Responsible for RA-Induced Differentiation of HL-60 Myeloblastic Leukemia Cells.PLoS One2015
25895498YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.J Hematol Oncol2015
25293778BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.Blood2014
23576564Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.Cancer Res2013
23928059Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma.Mol Cancer Res2013
21860020TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.Blood2011
19758707Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.J Neuroimmunol2009
17944900Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.Immunology2008
16552706Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease.Eur J Immunol2006
15048937Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants.J Neurosci Res2004
15352213T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice.J Neurosci Res2004
14743435CD4 T-cell epitopes of human alpha B-crystallin.J Neurosci Res2004
14515359Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity.J Neurosci Res2003
11045599Adrenocorticotropic hormone controls Concanavalin A activation of rat lymphocytes by modulating IL-2 production.Life Sci2000
  • 1 - 19 of 19

Recommended Authors

Merck & Co.
Career Start Year 1998
Number of shared co-authors 7
Transplant Research Center, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1998
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 7
University Children's Hospital Muenster
Career Start Year 1994
Number of shared co-authors 4
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1991
Number of shared co-authors 0
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 3
University of Michigan Medical School
Career Start Year 1989
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 1989
Number of shared co-authors 3
Helen Wills Neuroscience Institute, University of California berkeley
Career Start Year 1988
Number of shared co-authors 0
Stanford University School of Medicine
Career Start Year 1985
Number of shared co-authors 4
University of Vienna
Career Start Year 1985
Number of shared co-authors 0
Universite de Montreal
Career Start Year 1985
Number of shared co-authors 4
National Institute of Arthritis, National Institutes of Health
Career Start Year 1984
Number of shared co-authors 0
The University of Tokyo.
Career Start Year 1984
Number of shared co-authors 1
Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 1984
Number of shared co-authors 2
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 0
National Cancer Institute, National Institutes of Health
Career Start Year 1983
Number of shared co-authors 5
Technische Universitat Munchen
Career Start Year 1981
Number of shared co-authors 2
Vanderbilt University
Career Start Year 1981
Number of shared co-authors 1
University of Nebraska Medical Center
Career Start Year 1980
Number of shared co-authors 0
St. Anna Children's Hospital, Medical University of Vienna
Career Start Year 1980
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 23
8Benaroya Research Institute
Career Start Year 1978
Number of shared co-authors 1
University of Pennsylvania Department of Pathology & Laboratory Medicine
Career Start Year 1978
Number of shared co-authors 0
University of California San Diego
Career Start Year 1977
Number of shared co-authors 1
National Cancer Institute, National Institutes of Health
Career Start Year 1977
Number of shared co-authors 0
Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital
Career Start Year 1976
Number of shared co-authors 2
National Cancer Institute
Career Start Year 1976
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 1975
Number of shared co-authors 0
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1970
Number of shared co-authors 4

Collaborators

Oregon Health & Science University
Co-authored papers 10
Oregon Health & Science University School of Medicine
Co-authored papers 6
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Oregon Health and Science University
Co-authored papers 4
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Huntsman Cancer Institute, University of Utah
Co-authored papers 3
Oregon Health & Science University, University of California Berkeley
Co-authored papers 3
University of Utah Huntsman Cancer Institute
Co-authored papers 3
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital
Co-authored papers 2
Knight Cardiovascular Institute, Oregon Health and Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital
Co-authored papers 2
Knight Cardiovascular Institute, Oregon Health and Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Oregon Health & Science University
Co-authored papers 2
Children's Hospital of Philadelphia
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Fred Hutchinson Cancer Research Centre
Co-authored papers 2
MRC Weatherall Institute of Molecular Medicine, University of Oxford
Co-authored papers 2
Oregon Health & Science University, USA [2] Knight Cancer Institute
Co-authored papers 2
Cancer Early Detection Advanced Research Center, Oregon Health & Science University
Co-authored papers 2
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
St Jude Children's Research Hospital
Co-authored papers 2
Oregon Health & Science University
Co-authored papers 2
University of Washington
Co-authored papers 2